person · Reporting owner

VERNON W ANTHONY

Disclosed activity across 7 companies

Tapewire entity: 40917
SEC CIK: 0001369091

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Intersect ENT, Inc.XENT · Entity 127294	Director	June 04, 2020	June 08, 2020
MCCORMICK & CO INCMKC · Entity 1416	Director	February 15, 2026	February 18, 2026
NovoCure LtdNVCR · Entity 4494	Director	June 03, 2026	June 05, 2026
Nuvation Bio Inc.NUVB · Entity 4384	Director	May 21, 2026	May 27, 2026
Sio Gene Therapies Inc.AXON · Entity 130622	Director	May 15, 2017	May 16, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Intersect ENT, Inc.

Report date June 04, 2020 · Filed June 08, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,383	Reported balance After 2020-06-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-06-04 · Grant · Acquired 5,011 · Balance 11,383 F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2021. F2: Includes 5,011 restricted stock units.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.84 · Expires 2030-06-03	Direct	9,666	Reported balance After 2020-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-06-04 · Grant · Acquired 9,666 · Balance 9,666 F3: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2021.

F2: Includes 5,011 restricted stock units.

F3: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2020.

MCCORMICK & CO INC

Report date February 15, 2026 · Filed February 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock - VotingSEC Table I · non-derivative	Direct	14,048	Reported balance After 2026-02-15 transaction · row 1 1 source row Row 1 · 2026-02-15 · Exercise / conversion · Acquired 2,222 · Balance 14,048 F1: Restricted Stock Units; No purchase price required.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-02-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-15 · Exercise / conversion · Disposed 2,222 · Balance 0 F1: Restricted Stock Units; No purchase price required. F3: The Restricted Stock Units granted on February 7, 2025. F2: The reported Restricted Stock Units entitles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted Stock Units; No purchase price required.

F2: The reported Restricted Stock Units entitles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant.

F3: The Restricted Stock Units granted on February 7, 2025.

NovoCure Ltd

Report date June 03, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	209,267	Reported balance After 2026-06-03 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-03 · Grant · Acquired 11,610 · Balance 209,267 F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2036-06-03	Direct	16,999	Reported balance After 2026-06-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-03 · Grant · Acquired 16,999 · Balance 16,999 F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Nuvation Bio Inc.

Report date May 21, 2026 · Filed May 27, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.79 · Expires 2036-05-20	Direct	123,397	Reported balance After 2026-05-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-21 · Grant · Acquired 123,397 · Balance 123,397 F1: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

Sio Gene Therapies Inc.

Report date May 15, 2017 · Filed May 16, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.90 · Expires 2027-05-14	Direct	70,000	Reported balance After 2017-05-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-05-15 · Grant · Acquired 70,000 · Balance 70,000 F1: This option vests over a period of three years, with one third of the common shares underlying the option vesting on each of the first, second and third anniversaries of April 7, 2017, the date of the Reporting Person's appointment to the Issuer's Board of Directors. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests over a period of three years, with one third of the common shares underlying the option vesting on each of the first, second and third anniversaries of April 7, 2017, the date of the Reporting Person's appointment to the Issuer's Board of Directors. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MEDIVATION, INC.

Report date September 28, 2016 · Filed September 30, 2016

Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-09-28 transaction · row 1 1 source row Row 1 · 2016-09-28 · Other · Disposed 17,742 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2: Includes 2,972 unvested shares subject to a restricted stock award.
Common StockSEC Table I · non-derivative	IndirectSpouse's Trust	Reported balance After 2016-09-28 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2016-09-28 · Other · Disposed 15,000 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2019-06-30	Direct	Reported balance After 2016-09-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-09-28 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.21 · Expires 2020-06-30	Direct	Reported balance After 2016-09-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-09-28 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2021-07-15	Direct	Reported balance After 2016-09-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-09-28 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.74 · Expires 2022-07-16	Direct	Reported balance After 2016-09-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2016-09-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.60 · Expires 2023-06-28	Direct	Reported balance After 2016-09-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2016-09-28 · Disposition to issuer · Disposed 12,232 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.89 · Expires 2024-06-27	Direct	Reported balance After 2016-09-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2016-09-28 · Disposition to issuer · Disposed 9,584 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.45 · Expires 2025-06-16	Direct	Reported balance After 2016-09-28 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2016-09-28 · Disposition to issuer · Disposed 6,284 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.89 · Expires 2026-06-22	Direct	Reported balance After 2016-09-28 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2016-09-28 · Disposition to issuer · Disposed 6,228 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.

F2: Includes 2,972 unvested shares subject to a restricted stock award.

F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

WHITEWAVE FOODS Co

Report date April 12, 2017 · Filed April 13, 2017

Section 16 reporting ended · disclosed 2017-04-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
common stockSEC Table I · non-derivative	Direct	Reported balance After 2017-04-12 transaction · row 1 1 source row Row 1 · 2017-04-12 · Disposition to issuer · Disposed 6,300 · Balance 0 F1: At the effective time of the merger with Danone S.A., each outstanding share of WhiteWave common stock automatically was converted into the right to receive the $56.25 merger consideration per share in cash.
stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.91 · Expires 2026-01-01	Direct	Reported balance After 2017-04-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-04-12 · Disposition to issuer · Disposed 1,226 · Balance 0 F2: At the effective time of the merger, each stock option was cancelled in exchange for a per share cash payment equal to the difference between the $56.25 merger consideration per share and the exercise price of the stock option.
stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.09 · Expires 2026-02-15	Direct	Reported balance After 2017-04-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-04-12 · Disposition to issuer · Disposed 5,376 · Balance 0 F2: At the effective time of the merger, each stock option was cancelled in exchange for a per share cash payment equal to the difference between the $56.25 merger consideration per share and the exercise price of the stock option.

Filing footnotes · ownership attribution and instrument terms

F1: At the effective time of the merger with Danone S.A., each outstanding share of WhiteWave common stock automatically was converted into the right to receive the $56.25 merger consideration per share in cash.

F2: At the effective time of the merger, each stock option was cancelled in exchange for a per share cash payment equal to the difference between the $56.25 merger consideration per share and the exercise price of the stock option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 03, 2026 Filed Jun 5, 2026 20:25 UTC	NovoCure Ltd NVCR · Entity 4494	GrantStock Option (Right to Buy) · Derivative	16,999	$0.00 Strike: $16.15	$0.00	Disclosure SEC source: 0001369091-26-000005 · primarydocument.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,999 Underlying: Ordinary Shares · 16,999 shares Expires 2036-06-03 F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Read SEC document
June 03, 2026 Filed Jun 5, 2026 20:25 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOrdinary Shares	11,610	$0.00	$0.00	Disclosure SEC source: 0001369091-26-000005 · primarydocument.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,267 F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Read SEC document
June 02, 2026 Filed Jun 3, 2026 20:52 UTC	NovoCure Ltd NVCR · Entity 4494	SaleOrdinary Shares	2,945	$15.77	$46,444.71	Disclosure SEC source: 0001369091-26-000004 · primarydocument.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,657 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $15.65 USD to $15.88 USD; the price reported above reflects the weighted average sale price. Read SEC document
May 21, 2026 Filed May 27, 2026 00:07 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	123,397	$0.00 Strike: $4.79	$0.00	Disclosure SEC source: 0001369091-26-000003 · form4-05272026_120552.xml · derivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,397 Underlying: Class A Common Stock · 123,397 shares Expires 2036-05-20 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document
April 28, 2026 Filed Apr 28, 2026 20:27 UTC	NovoCure Ltd NVCR · Entity 4494	Exercise / conversionStock Option (Right to Buy) · Derivative	21,500	$0.00 Strike: $11.39	$0.00	Disclosure SEC source: 0001369091-26-000002 · primarydocument.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,500 shares Expires 2026-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
April 28, 2026 Filed Apr 28, 2026 20:27 UTC	NovoCure Ltd NVCR · Entity 4494	Exercise / conversionOrdinary Shares	21,500	$11.39	$244,885.00	Disclosure SEC source: 0001369091-26-000002 · primarydocument.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 15, 2026 Filed Feb 18, 2026 18:52 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionRestricted Stock Units · Derivative	2,222	Not disclosed	Not disclosed	Disclosure SEC source: 0000063754-26-000123 · form4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock - Voting · 2,222 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units; No purchase price required. F3 · price: The Restricted Stock Units granted on February 7, 2025. F2 · derivative.exercise_date: The reported Restricted Stock Units entitles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant. F2 · derivative.expiration_date: The reported Restricted Stock Units entitles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant. Read SEC document
February 15, 2026 Filed Feb 18, 2026 18:52 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionCommon Stock - Voting	2,222	Not disclosed	Not disclosed	Disclosure SEC source: 0000063754-26-000123 · form4.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,048 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units; No purchase price required. Read SEC document
June 04, 2025 Filed Jun 6, 2025 20:13 UTC	NovoCure Ltd NVCR · Entity 4494	GrantStock Option (Right to Buy) · Derivative	16,697	$0.00 Strike: $16.72	$0.00	Disclosure SEC source: 0001562180-25-004555 · primarydocument.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,697 Underlying: Ordinary Shares · 16,697 shares Expires 2035-06-04 F2 · derivative.exercise_date: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders. Read SEC document
June 04, 2025 Filed Jun 6, 2025 20:13 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOrdinary Shares	11,215	$0.00	$0.00	Disclosure SEC source: 0001562180-25-004555 · primarydocument.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,102 F1 · security: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2026 annual general meeting of shareholders. Read SEC document
June 03, 2025 Filed Jun 4, 2025 20:14 UTC	NovoCure Ltd NVCR · Entity 4494	SaleOrdinary Shares	999	$17.35	$17,329.25	Disclosure SEC source: 0001562180-25-004429 · primarydocument.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,887 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.1025 USD to $17.50 USD; the price reported above reflects the weighted average sale price. F3 · balance_after: Amended total to correct prior mathematical error. Read SEC document
May 21, 2025 Filed May 23, 2025 20:05 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	292,983	$0.00 Strike: $2.03	$0.00	Disclosure SEC source: 0001415889-25-014421 · form4-05232025_040510.xml · derivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 292,983 Underlying: Class A Common Stock · 292,983 shares Expires 2035-05-20 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2025); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document
March 15, 2025 Filed Mar 18, 2025 21:56 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionRestricted Stock Units · Derivative	1,344	$0.00	$0.00	Disclosure SEC source: 0001062993-25-005760 · form4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock - Voting · 1,344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units; No purchase price required. F3 · price: The Restricted Stock Units granted on March 27, 2024. F2 · derivative.exercise_date: The reported Restricted Stock Units entitles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant. F2 · derivative.expiration_date: The reported Restricted Stock Units entitles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant. Read SEC document
March 15, 2025 Filed Mar 18, 2025 21:56 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionCommon Stock - Voting	1,344	$0.00	$0.00	Disclosure SEC source: 0001062993-25-005760 · form4.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units; No purchase price required. Read SEC document
February 07, 2025 Filed Feb 14, 2025 15:19 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantRestricted Stock Units · Derivative	2,222	$0.00	$0.00	Disclosure SEC source: 0001062993-25-002439 · form4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,222 Underlying: Common Stock - Voting · 2,222 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Unit represents a contingent right to receive one share of Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in full on 2/15/2026 and are settled in an equal number of shares of McCormick stock. F2 · derivative.expiration_date: The Restricted Stock Units vest in full on 2/15/2026 and are settled in an equal number of shares of McCormick stock. Read SEC document
September 03, 2024 Filed Sep 5, 2024 21:57 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	200,801	$0.00 Strike: $2.98	$0.00	Disclosure SEC source: 0001415889-24-022968 · form4-09052024_090933.xml · derivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,801 Underlying: Class A Common Stock · 200,801 shares Expires 2034-09-02 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (September 3, 2024); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document
June 05, 2024 Filed Jun 6, 2024 21:43 UTC	NovoCure Ltd NVCR · Entity 4494	GrantStock Option (Right to Buy) · Derivative	6,229	$0.00 Strike: $23.13	$0.00	Disclosure SEC source: 0001562180-24-004761 · primarydocument.xml · derivative · entry 3 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,229 Underlying: Ordinary Shares · 6,229 shares Expires 2034-06-04 F3 · derivative.exercise_date: Options to buy 6,229 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders. Read SEC document
June 05, 2024 Filed Jun 6, 2024 21:43 UTC	NovoCure Ltd NVCR · Entity 4494	GrantRestricted Stock Units	4,053	$0.00	$0.00	Disclosure SEC source: 0001562180-24-004761 · primarydocument.xml · nonDerivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,850 F2 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2025 annual general meeting of shareholders. Read SEC document
June 04, 2024 Filed Jun 6, 2024 21:43 UTC	NovoCure Ltd NVCR · Entity 4494	SaleOrdinary Shares	964	$23.89	$23,032.85	Disclosure SEC source: 0001562180-24-004761 · primarydocument.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,833 F1 · price: This transaction was executed in multiple trades at prices ranging from $23.78 USD to $24.00 USD; the price reported above reflects the weighted average sale price. Read SEC document
March 27, 2024 Filed Mar 29, 2024 16:17 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantOptions - Right to Buy · Derivative	3,732	$0.00 Strike: $76.03	$0.00	Disclosure SEC source: 0001062993-24-007430 · form4.xml · derivative · entry 3 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,732 Underlying: Common Stock - Voting · 3,732 shares Expires not disclosed F3 · derivative.exercise_date: The options vest in full on 3/15/2025. F3 · derivative.expiration_date: The options vest in full on 3/15/2025. Read SEC document
March 27, 2024 Filed Mar 29, 2024 16:17 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantRestricted Stock Units · Derivative	1,344	$0.00	$0.00	Disclosure SEC source: 0001062993-24-007430 · form4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,344 Underlying: Common Stock - Voting · 1,344 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Unit represents a contingent right to receive one share of Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in full on 3/15/2025 and are settled in an equal number of shares of McCormick stock. F2 · derivative.expiration_date: The Restricted Stock Units vest in full on 3/15/2025 and are settled in an equal number of shares of McCormick stock. Read SEC document
March 15, 2024 Filed Mar 19, 2024 19:40 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionRestricted Stock Units · Derivative	1,255	$0.00	$0.00	Disclosure SEC source: 0001062993-24-006766 · form4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock - Voting · 1,255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units; No purchase price required. F3 · price: The Restricted Stock Units granted on March 29, 2023. F2 · derivative.exercise_date: The reported Restricted Stock Units entitles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant. F2 · derivative.expiration_date: The reported Restricted Stock Units entitles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant. Read SEC document
March 15, 2024 Filed Mar 19, 2024 19:40 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionCommon Stock - Voting	1,255	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-24-006766 · form4.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units; No purchase price required. Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:05 UTC	NovoCure Ltd NVCR · Entity 4494	GrantStock Option (Right to Buy) · Derivative	6,277	$0.00 Strike: $48.66	$0.00	Disclosure SEC source: 0001562180-23-005017 · primarydocument.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,277 Underlying: Ordinary Shares · 6,277 shares Expires 2033-06-06 F2 · derivative.exercise_date: Options to buy 6,277 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document
June 07, 2023 Filed Jun 9, 2023 20:05 UTC	NovoCure Ltd NVCR · Entity 4494	GrantRestricted Stock Units	3,853	$0.00	$0.00	Disclosure SEC source: 0001562180-23-005017 · primarydocument.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,797 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document
May 15, 2023 Filed May 17, 2023 21:14 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	366,744	$0.00 Strike: $1.64	$0.00	Disclosure SEC source: 0001209191-23-030283 · doc4.xml · derivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 366,744 Underlying: Class A Common Stock · 366,744 shares Expires 2033-05-14 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 15, 2024); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document
March 29, 2023 Filed Mar 31, 2023 17:51 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantOptions- Right to Buy · Derivative	3,101	$0.00 Strike: $81.79	$0.00	Disclosure SEC source: 0001062993-23-008150 · form4.xml · derivative · entry 3 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,101 Underlying: Common Stock - Voting · 3,101 shares Expires not disclosed F3 · derivative.exercise_date: The options vest in full on 3/15/2024. F3 · derivative.expiration_date: The options vest in full on 3/15/2024. Read SEC document
March 29, 2023 Filed Mar 31, 2023 17:51 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantRestricted Stock Units · Derivative	1,255	$0.00	$0.00	Disclosure SEC source: 0001062993-23-008150 · form4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,255 Underlying: Common Stock - Voting · 1,255 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Unit represents a contingent right to receive one share of Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in full on 3/15/2024 and are settled in an equal number of shares of McCormick stock. F2 · derivative.expiration_date: The Restricted Stock Units vest in full on 3/15/2024 and are settled in an equal number of shares of McCormick stock. Read SEC document
March 15, 2023 Filed Mar 17, 2023 00:39 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionRestricted Stock Units · Derivative	1,044	$0.00	$0.00	Disclosure SEC source: 0001062993-23-007104 · form4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock - Voting · 1,044 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units; No purchase price required. F3 · price: Restricted Stock Units granted on March 30, 2022. F2 · derivative.exercise_date: The reported Restricted Stock Units entitles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant. F2 · derivative.expiration_date: The reported Restricted Stock Units entitles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant. Read SEC document
March 15, 2023 Filed Mar 17, 2023 00:39 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionCommon Stock - Voting	1,044	$0.00	$0.00	Disclosure SEC source: 0001062993-23-007104 · form4.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units; No purchase price required. Read SEC document
June 08, 2022 Filed Jun 10, 2022 20:10 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOptions to Buy Ordinary Shares · Derivative	8,700	$0.00 Strike: $77.25	$0.00	Disclosure SEC source: 0001645113-22-000052 · wf-form4_165489178577472.xml · derivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,700 Underlying: Ordinary Shares · 8,700 shares Expires 2032-06-08 F1 · derivative.exercise_date: Options to buy 8,700 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2023 annual general meeting of shareholders. Read SEC document
May 16, 2022 Filed May 18, 2022 20:51 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	118,784	$0.00 Strike: $4.05	$0.00	Disclosure SEC source: 0001209191-22-030086 · doc4.xml · derivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,784 Underlying: Class A Common Stock · 118,784 shares Expires 2032-05-15 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document
May 16, 2022 Filed Jun 28, 2022 23:11 UTC Amendment	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	140,713	$0.00 Strike: $4.05	$0.00	Disclosure SEC source: 0001209191-22-039679 · doc4a.xml · derivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,713 Underlying: Class A Common Stock · 140,713 shares Expires 2032-05-15 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 16, 2023); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document
March 30, 2022 Filed Apr 1, 2022 15:22 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantOptions- Right to Buy · Derivative	2,711	$0.00 Strike: $97.26	$0.00	Disclosure SEC source: 0001062993-22-009146 · form4.xml · derivative · entry 3 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,711 Underlying: Common Stock - Voting · 2,711 shares Expires not disclosed F3 · derivative.exercise_date: The options vest in full on March 15, 2023. F3 · derivative.expiration_date: The options vest in full on March 15, 2023. Read SEC document
March 30, 2022 Filed Apr 1, 2022 15:22 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantRestricted Stock Units · Derivative	1,044	$0.00	$0.00	Disclosure SEC source: 0001062993-22-009146 · form4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,044 Underlying: Common Stock - Voting · 1,044 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Unit represents a contingent right to receive one share of Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in full on 3/15/2023 and are settled in an equal number of shares of McCormick stock. F2 · derivative.expiration_date: The Restricted Stock Units vest in full on 3/15/2023 and are settled in an equal number of shares of McCormick stock. Read SEC document
March 15, 2022 Filed Mar 17, 2022 18:24 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionRestricted Stock Units · Derivative	1,139	$0.00	$0.00	Disclosure SEC source: 0001062993-22-007999 · form4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock - Voting · 1,139 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units; No purchase price required. F4 · price: Restricted Stock Units granted on March 31, 2021. F3 · derivative.exercise_date: The reported Restricted Stock Units entitles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant. F3 · derivative.expiration_date: The reported Restricted Stock Units entitles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant. Read SEC document
March 15, 2022 Filed Mar 17, 2022 18:24 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionCommon Stock - Voting	1,139	Not disclosed	Not disclosed	Disclosure SEC source: 0001062993-22-007999 · form4.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units; No purchase price required. F2 · balance_after: The totals reported in the reported RSU vesting do not include 17 shares that, due to administrative error, were incorrectly included in the Reporting Person's Form 4 reporting the RSU grant. Read SEC document
October 29, 2021 Filed Nov 3, 2021 01:30 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	45,229	$0.00 Strike: $9.17	$0.00	Disclosure SEC source: 0001209191-21-062587 · doc4.xml · derivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,229 Underlying: Class A Common Stock · 45,229 shares Expires 2031-10-28 F1 · derivative.exercise_date: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (October 29, 2022); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date. Read SEC document
June 09, 2021 Filed Jun 11, 2021 20:22 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOptions to Buy Ordinary Shares · Derivative	1,499	$0.00 Strike: $211.89	$0.00	Disclosure SEC source: 0001645113-21-000077 · wf-form4_162344290145800.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,499 Underlying: Ordinary Shares · 1,499 shares Expires 2031-06-09 F2 · derivative.exercise_date: Options to buy 1,499 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders. Read SEC document
June 09, 2021 Filed Jun 11, 2021 20:22 UTC	NovoCure Ltd NVCR · Entity 4494	GrantRestricted Stock Units	814	$0.00	$0.00	Disclosure SEC source: 0001645113-21-000077 · wf-form4_162344290145800.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,944 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2022 annual general meeting of shareholders. Read SEC document
March 31, 2021 Filed Apr 2, 2021 15:01 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantOptions - Right to Buy · Derivative	3,268	$0.00 Strike: $89.16	$0.00	Disclosure SEC source: 0000063754-21-000087 · edgar.xml · derivative · entry 3 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,268 Underlying: Common Stock - Voting · 3,268 shares Expires not disclosed F3 · derivative.exercise_date: The options vest in full on 3/15/2022. F3 · derivative.expiration_date: The options vest in full on 3/15/2022. Read SEC document
March 31, 2021 Filed Apr 2, 2021 15:01 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantRestricted Stock Units · Derivative	1,156	$0.00	$0.00	Disclosure SEC source: 0000063754-21-000087 · edgar.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,156 Underlying: Common Stock - Voting · 1,156 shares Expires not disclosed F1 · derivative.exercise_price: The Restricted Stock Unit represents a contingent right to receive one share of Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in full on 3/15/2022 and are settled in an equal number of shares of McCormick stock. F2 · derivative.expiration_date: The Restricted Stock Units vest in full on 3/15/2022 and are settled in an equal number of shares of McCormick stock. Read SEC document
March 15, 2021 Filed Mar 16, 2021 20:29 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionRestricted Stock Units · Derivative	1,468	$0.00	$0.00	Disclosure SEC source: 0000063754-21-000051 · edgar.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock - Voting · 1,468 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units; No purchase price required. F4 · price: Restricted Stock Units granted on April 1, 2020. F3 · derivative.exercise_date: The reported Restricted Stock Units entiles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant. F3 · derivative.expiration_date: The reported Restricted Stock Units entiles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant. Read SEC document
March 15, 2021 Filed Mar 16, 2021 20:29 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionCommon Stock - Voting	1,468	Not disclosed	Not disclosed	Disclosure SEC source: 0000063754-21-000051 · edgar.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,044 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units; No purchase price required. F2 · balance_after: Amounts reported herein are based on the Issuer's 2 for 1 stock split of its common and common stock non-voting, effective November 30, 2020. Read SEC document
February 10, 2021 Filed Feb 12, 2021 22:56 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	187,658	Not disclosed Strike: $1.74	Not disclosed	Disclosure SEC source: 0001209191-21-010362 · doc4.xml · derivative · entry 4 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,658 Underlying: Class A Common Stock · 187,658 shares Expires 2030-01-21 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F6 · price: Received in exchange for an option to purchase 187,658 shares of Legacy Nuvation Class A Common Stock. F5 · derivative.exercise_date: Options vest in 48 equal monthly installments from July 17, 2019. Read SEC document
February 10, 2021 Filed Feb 12, 2021 22:56 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantStock Option (Right to Buy) · Derivative	51,703	Not disclosed Strike: $4.60	Not disclosed	Disclosure SEC source: 0001209191-21-010362 · doc4.xml · derivative · entry 3 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,703 Underlying: Class A Common Stock · 51,703 shares Expires 2030-10-04 F1 · kind: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). F4 · price: Received in exchange for an option to purchase 51,703 shares of Legacy Nuvation Class A Common Stock. F3 · derivative.exercise_date: Options vest in 48 equal monthly installments from October 5, 2020. Read SEC document
June 10, 2020 Filed Jun 12, 2020 22:11 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOptions to Buy Ordinary Shares · Derivative	5,101	$0.00 Strike: $67.89	$0.00	Disclosure SEC source: 0001645113-20-000089 · wf-form4_159199985639264.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,101 Underlying: Ordinary Shares · 5,101 shares Expires 2030-06-10 F2 · derivative.exercise_date: Options to buy 5,101 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document
June 10, 2020 Filed Jun 12, 2020 22:11 UTC	NovoCure Ltd NVCR · Entity 4494	GrantRestricted Stock Units	2,541	$0.00	$0.00	Disclosure SEC source: 0001645113-20-000089 · wf-form4_159199985639264.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,130 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document
June 04, 2020 Filed Jun 8, 2020 16:51 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Option (right to buy) · Derivative	9,666	$0.00 Strike: $11.84	$0.00	Disclosure SEC source: 0001562180-20-004317 · primarydocument.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,666 Underlying: Common Stock · 9,666 shares Expires 2030-06-03 F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2020. Read SEC document
June 04, 2020 Filed Jun 8, 2020 16:51 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantCommon Stock	5,011	$0.00	$0.00	Disclosure SEC source: 0001562180-20-004317 · primarydocument.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,383 F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2021. F2 · balance_after: Includes 5,011 restricted stock units. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.